14 California Locations + Online

GLP-1 Medications for Weight Loss: How They Work, Results, and Safe Use

Muscle Loss on GLP-1 Medications: How to Protect Your Lean Mass

Medically reviewed by: Last updated: Reviewed for: Clinical accuracy, alignment with current obesity-medicine guidance and FDA labeling, and JumpstartMD treatment protocols.

In a Nutshell

When you lose weight on a GLP-1 medication, not all of that weight is fat. In the body-composition sub-studies of the major trials, roughly 25% of the weight lost on tirzepatide (Zepbound®, Mounjaro®) was lean mass and about 75% was fat 4, while on semaglutide (Wegovy®, Ozempic®) lean tissue made up an even larger share — by some measures up to 40% of total weight lost 2. That muscle is not just cosmetic: it drives your metabolism, your strength, and your ability to keep the weight off after you stop the medication.

The good news: muscle loss on a GLP-1 is largely preventable. Lean-mass changes are driven more by what you do — protein intake and resistance training — than by the drug itself. In a 2025 case series, two of three patients actually gained lean tissue while losing 13-33% of body weight, by lifting weights 3-5 days a week and eating enough protein 8. The three levers that protect muscle are: enough protein (about 1.2-1.6 grams per kilogram of body weight per day), regular resistance training, and tracking body composition — not just the scale.

This is exactly why JumpstartMD measures lean mass with InBody® body-composition scanning at visits rather than relying on the bathroom scale: the goal of treatment is to lose fat, not strength — and you can't manage what you don't measure.

How Much Muscle Do You Actually Lose on a GLP-1?

Total body weight is a blunt number — it can't tell you whether you're losing the fat you want gone or the muscle you need to keep. To see that, researchers use DXA (dual-energy X-ray absorptiometry) scans, which separate fat from lean (mostly muscle) mass. Several trials ran DXA sub-studies, and they paint a consistent picture.

Tirzepatide (SURMOUNT-1 sub-study). SURMOUNT-1 established tirzepatide's headline efficacy — up to −20.9% body weight at 72 weeks 3 — and its DXA sub-study shows what that weight was made of. Among 160 participants scanned at baseline and week 72, those on tirzepatide lost 21.3% of body weight, 33.9% of fat mass, and 10.9% of lean mass 4. Do the arithmetic and about 75% of the weight lost was fat and about 25% was lean mass — and that same 75/25 split also held in the placebo group 4. In other words, this fat-to-lean ratio is roughly what happens with any substantial weight loss, not a unique flaw of the medication.

Semaglutide (STEP 1 sub-study). STEP 1 showed semaglutide 2.4 mg cut body weight by a mean −14.9% at 68 weeks 1. Its 140-person DXA analysis breaks that down: a 15.0% drop in body weight, a 19.3% reduction in fat mass, and a 9.7% reduction in lean body mass 2. Because lean mass started as a large fraction of body weight, that 9.7% worked out to roughly 40% of the total weight lost coming from lean tissue 2 — the higher end of the range you will see quoted.

Putting it together. Across recent trials, lean soft tissue has accounted for roughly 25% to 40% of weight lost 8. The cross-trial comparison — tirzepatide's 10.9% lean reduction versus semaglutide's 9.7% — looks like tirzepatide costs slightly more muscle, but these came from two different trials with different participants, not a head-to-head study, so the gap shouldn't be over-read. The useful takeaway: both medications cause meaningful lean-mass loss, and both respond to the same protective strategies.

Why does the body give up muscle during weight loss? On a GLP-1, three things converge: far fewer calories (so the body taps some muscle for energy), appetite suppression that often means less protein specifically, and a tendency to become less active rather than more. The drug accelerates weight loss; your habits decide how much of it is fat versus muscle.

Why Losing Muscle Matters

Muscle is metabolically active tissue, and losing it carries consequences beyond how you look:

  • Slower metabolism. Lean mass is a major driver of your resting metabolic rate. Lose muscle and your "calorie budget" shrinks, which can stall weight loss and makes regain easier.
  • Strength and function. Muscle lets you climb stairs, carry groceries, and stay independent as you age; rapid loss means fatigue and weakness.
  • Regain risk — the one that matters most for results. When people stop a GLP-1 and regain weight, the regained weight is disproportionately fat. Lose muscle on the way down and regain fat on the way back up, and your body composition ends up worse than where you started.
  • Sarcopenic obesity. Losing muscle while still carrying excess fat is a recognized concern, especially in older adults and in women going through menopause, where age- and hormone-related muscle loss already stack on top of the GLP-1 effect.

This isn't a reason to avoid these medications — the metabolic and cardiovascular benefits of GLP-1 weight loss are real and substantial. It's a reason to pay attention to how you lose the weight, not just how much.

How to Prevent Muscle Loss on GLP-1 Medications

There are three evidence-based interventions, and they work together. None of them is optional if your goal is to protect strength while losing fat.

1. Eat enough protein

Protein is the single most important nutritional lever. During a calorie deficit, higher protein intake preserves lean mass and improves body composition compared with standard intake 7. The challenge on a GLP-1 is that appetite suppression makes it easy to under-eat protein specifically — so it has to become a deliberate priority.

How much? For muscle preservation during weight loss, aim for roughly 1.2-1.6 grams of protein per kilogram of body weight per day — well above the baseline RDA of 0.8 g/kg, which evidence shows is too low to protect lean mass during weight loss, especially in older adults 7. People who add resistance training, and those who are older, generally do best toward the higher end (up to about 1.6-2.2 g/kg).

Protein needs by body weight

Body weightBody weight (kg)Muscle-preservation target (1.2-1.6 g/kg)Higher target for resistance trainers (~2.0 g/kg)
130 lb59 kg71-94 g/day~118 g/day
150 lb68 kg82-109 g/day~136 g/day
170 lb77 kg93-123 g/day~154 g/day
190 lb86 kg103-138 g/day~172 g/day
210 lb95 kg114-152 g/day~191 g/day
230 lb104 kg125-167 g/day~209 g/day
250 lb113 kg136-181 g/day~227 g/day
280 lb127 kg152-203 g/day~254 g/day

These targets are based on current body weight. At higher BMIs, clinicians often calculate protein from an adjusted or goal body weight to avoid overestimating, and people with kidney disease need an individualized (often lower) target — so use this table as a starting point to discuss with your clinician, not a fixed prescription.

Practical tips that survive a suppressed appetite:

  • Eat protein first at each meal, before carbs and fats, so you get it in before you feel full.
  • Spread it across 3-4 meals (roughly 25-40 g each) — muscle protein synthesis responds best to protein distributed through the day.
  • Lean on protein-dense foods: Greek yogurt, eggs, chicken, fish, lean beef, tofu, cottage cheese, and a protein shake when solid food feels like too much.
  • If nausea or early fullness is making protein hard, smaller high-protein mini-meals and liquid protein often go down easier.

2. Do resistance training

Diet alone protects some muscle; resistance training is what actually preserves and rebuilds it. In a landmark trial of weight-loss maintenance, adding a structured exercise program (not just the medication) produced better body composition than the drug alone, roughly doubling the improvement in body-fat percentage 6. The signal is consistent: the muscle you load is the muscle your body keeps.

A practical, evidence-aligned protocol:

  • 2-4 sessions per week at a moderately hard effort (3-5 if you are able).
  • Compound movements that work large muscle groups — squats, deadlifts or hip hinges, presses, rows, and lunges — give the most return per minute.
  • Progressive overload: gradually increase weight, reps, or sets over time. Doing the same thing forever stops working.
  • Add about 150 minutes of moderate aerobic activity weekly for heart and metabolic health, but know that cardio is not a substitute for lifting when the goal is muscle.

Never lifted before? That's an opportunity, not a barrier — form matters more than load, and a few sessions with a trainer or physical therapist to learn the movements is worth it.

3. Track body composition, not just the scale

The scale cannot tell you whether you are losing fat or muscle — and during a GLP-1 program, that distinction is the whole game. Body-composition monitoring (DXA or, as JumpstartMD uses, InBody® bioelectrical-impedance scanning) shows you the breakdown, so a stalled scale that is actually fat down, muscle up doesn't get mistaken for failure, and silent muscle loss gets caught early enough to fix with more protein or training. Watching only total weight is how people lose strength without realizing it until it is gone.

A note on dose and pace

Aggressive, rapid weight loss tends to cost more muscle than steadier loss — one more reason dose titration belongs with a clinician watching your body composition and adjusting the pace. There is also early pharmacologic research: in the BELIEVE trial, adding the muscle-preserving agent bimagrumab to semaglutide cut lean-mass loss from 7.4% to just 2.9% while increasing fat loss 5. Such combinations are investigational and not FDA-approved for this use, but they underscore the central message — protecting muscle is a solvable problem.

Is This Normal? When to Call Your Clinician

Some lean-mass loss alongside large fat loss is expected and not alarming in itself — especially if you're eating protein, training, and your strength is holding up. It's worth checking in with your clinician when:

  • You feel noticeably weaker — struggling with stairs, carrying bags, or standing from a chair.
  • You're losing weight very fast (more than roughly 1-2% of body weight per week, sustained), which raises the muscle-loss share.
  • You can't hit your protein target because of persistent nausea, early fullness, or food aversion.
  • A body-composition scan shows lean mass dropping faster than expected, or fat loss has stalled while lean mass keeps falling.
  • You're older or postmenopausal, where baseline muscle loss is already a concern and the margin for error is smaller.

Any of these is a cue to revisit your dose pace, nutrition, and training — not to abandon treatment, but to adjust it.

Red Flags — Seek Care Now

Muscle-loss prevention is usually a slow-burn issue, but certain symptoms warrant prompt medical attention because they may signal severe undernutrition, dehydration, or another problem:

  • Sudden, severe weakness, falls, or inability to get up — could indicate dangerous muscle loss or another acute problem.
  • Dark or cola-colored urine with muscle pain after exertion — possible rhabdomyolysis (muscle breakdown); seek urgent care.
  • Signs of severe malnutrition or dehydration: dizziness, fainting, confusion, very low food and fluid intake for days, or rapid involuntary weight loss far beyond what is expected.
  • Persistent inability to keep down food or fluids — get evaluated promptly; this also raises the risk of serious GI complications.

When in doubt, call your clinician the same day. For any life-threatening symptom, call 911 or go to the nearest emergency department.

What You Can Do About It

A practical plan — most of it is in your hands:

  1. Set a daily protein target from the table above and hit it consistently — the highest-impact, lowest-risk step.
  2. Start resistance training 2-4 times a week, even with bodyweight or light dumbbells at first, and progress gradually.
  3. Ask for a body-composition scan at baseline and periodically, so decisions rest on fat and muscle numbers rather than the scale alone.
  4. Coordinate dose and pace with a clinician who tracks lean mass and slows titration if muscle is dropping too fast — dose decisions belong with your care team, not a guess.
  5. Protect the result for the long haul: the muscle you preserve now is your best insurance against weight regain after stopping, because it keeps your metabolism higher.

Get Started with JumpstartMD

If you want to lose fat without sacrificing strength, you need a program built to measure the difference — and that is precisely what JumpstartMD was designed to do.

Founded in 2007 by Stanford-trained physicians, JumpstartMD builds every weight-loss plan around labs, hormones, and body composition, with peer-reviewed outcomes published in the Journal of Obesity. At the center of our GLP-1 care is InBody® body-composition scanning at your visit cadence, which tracks lean mass directly so you lose fat, not strength — important because up to 40% of the weight lost on a GLP-1 can be muscle without proper supervision. You're seen face-to-face by licensed clinicians — in person at our 14 California locations or online across California — and screened with a 69-biomarker lab panel so your plan reflects your actual physiology.

Our clinicians offer the full range of FDA-approved options — Ozempic®, Wegovy®, Zepbound®, Mounjaro®, and Rybelsus® — plus non-GLP-1 and no-medication plans, with flexible dosing, microdosing, and maintenance support. Every prescription follows clinician-managed titration, contraindication screening, and drug-interaction monitoring, with pace adjusted to your body-composition results so weight loss stays in the fat compartment. Health coaching and nutrition guidance — including hitting protein targets and building a resistance-training habit — are included in membership, and our step-down/taper protocols are built to protect the muscle and results you worked for after the medication phase ends.

You also pay personalized medication pricing — the cost of the dose you're actually prescribed, not a flat monthly fee. To make sure your weight loss is the right kind of weight loss, schedule a free, no-obligation consultation by phone or through our online form.

A clinician available to discuss your perimenopause and menopause symptoms
Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

See also the GLP-1 medications for weight loss pillar and, if menopause is part of your picture, our menopause symptoms hub — including perimenopause weight gain and visceral fat.

Frequently Asked Questions

How much lean mass is lost on tirzepatide?

In the SURMOUNT-1 body-composition sub-study, participants on tirzepatide lost about 10.9% of their lean mass over 72 weeks, alongside a 33.9% drop in fat mass and a 21.3% drop in total body weight 4. Translated into proportions, roughly 25% of the weight lost was lean mass and about 75% was fat — and that same ratio appeared in the placebo group too, which tells us it reflects weight loss in general rather than a unique tirzepatide effect 4. In absolute terms, that averaged out to roughly 5-6 kg of lean tissue. Crucially, this figure is not fixed: with adequate protein and resistance training, the lean-mass share can be reduced substantially 8.

How do I prevent muscle loss on GLP-1 medications?

Three strategies, used together: (1) eat enough protein — about 1.2-1.6 g per kg of body weight per day, prioritized at each meal; (2) do resistance training at least 2-3 times a week, focusing on compound movements with progressive overload; and (3) monitor body composition (DXA or InBody) instead of relying on the scale, so you can confirm you're losing fat, not muscle. A clinician-managed dose pace helps too — losing weight more gradually tends to spare more muscle.

Does tirzepatide cause more muscle loss than semaglutide?

Not in a way that's been proven head-to-head. In separate trials, tirzepatide reduced lean mass by about 10.9% 4 and semaglutide by about 9.7% 2 — close numbers, but from different study populations, so the small gap shouldn't be over-read. Both medications cause meaningful lean-mass loss, and both respond to the same protein-and-training strategies. The choice between them should rest on efficacy, tolerability, and your clinical situation, not on a muscle-loss difference that hasn't been directly demonstrated. See semaglutide vs tirzepatide for the full comparison.

Can you actually gain muscle while on a GLP-1?

Yes, it's possible for some people. In a 2025 case series, two of three patients on semaglutide or tirzepatide increased their lean soft tissue while losing 13-33% of body weight, by training with resistance 3-5 days a week and prioritizing protein; the third lost only 8.7% of weight as lean tissue 8. These are individual cases, not a guarantee — but they show that body composition is heavily influenced by what you do, not just by the medication.

Is muscle loss a reason not to take a GLP-1?

No. The cardiometabolic benefits of treating obesity with these medications are substantial, and muscle loss is largely preventable with protein, resistance training, and body-composition monitoring 6, 8. The takeaway isn't to avoid GLP-1s — it's to use them within a supervised program that measures lean mass and helps you protect it.

References

  1. J. P. H. Wilding, R. L. Batterham, S. Calanna, M. Davies, L. F. Van Gaal, I. Lingvay, B. M. McGowan, J. Rosenstock, M. T. D. Tran, T. A. Wadden, S. Wharton, K. Yokote, N. Zeuthen, R. F. Kushner; STEP 1 Study Group, "Once-weekly semaglutide in adults with overweight or obesity," New England Journal of Medicine, vol. 384, no. 11, pp. 989-1002, Mar. 2021, [Online]. Available: https://doi.org/10.1056/NEJMoa2032183. PMID: 33567185. [Accessed: Jun. 10, 2026].
  2. J. P. H. Wilding et al., "Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study," Journal of the Endocrine Society, vol. 5, no. Supplement_1, pp. A16-A17, May 2021, [Online]. Available: https://doi.org/10.1210/jendso/bvab048.030. PMCID: PMC8089287. [Accessed: Jun. 10, 2026].
  3. A. M. Jastreboff, L. J. Aronne, N. N. Ahmad, S. B. Wharton, L. Connery, B. Alves, A. Kiyosue, S. Zhang, B. Liu, M. C. Bunck, A. Stefanski; SURMOUNT-1 Investigators, "Tirzepatide once weekly for the treatment of obesity," New England Journal of Medicine, vol. 387, no. 3, pp. 205-216, Jul. 2022, [Online]. Available: https://doi.org/10.1056/NEJMoa2206038. PMID: 35658024. [Accessed: Jun. 10, 2026].
  4. M. Look et al., "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight," Diabetes, Obesity and Metabolism, vol. 27, no. 5, pp. 2720-2729, May 2025, [Online]. Available: https://doi.org/10.1111/dom.16275. [Accessed: Jun. 10, 2026].
  5. S. B. Heymsfield, L. J. Aronne, P. Montgomery, L. B. Klickstein, L. A. Coleman, K. Dole, L. Mindeholm, S. Spruill, X. Li, K. M. Attie, "Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial," Nature Medicine, vol. 32, no. 3, pp. 869-882, Mar. 2026, [Online]. Available: https://doi.org/10.1038/s41591-026-04204-0. [Accessed: Jun. 10, 2026].
  6. J. R. Lundgren, C. Janus, S. B. K. Jensen, C. R. Juhl, L. M. Olsen, R. M. Christensen, et al., "Healthy weight loss maintenance with exercise, liraglutide, or both combined," New England Journal of Medicine, vol. 384, no. 18, pp. 1719-1730, May 2021, [Online]. Available: https://doi.org/10.1056/NEJMoa2028198. PMID: 33951361. [Accessed: Jun. 10, 2026].
  7. J. Bauer, G. Biolo, T. Cederholm, M. Cesari, A. J. Cruz-Jentoft, J. E. Morley, S. Phillips, C. Sieber, P. Stehle, D. Teta, R. Visvanathan, E. Volpi, Y. Boirie, "Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group," Journal of the American Medical Directors Association, vol. 14, no. 8, pp. 542-559, Aug. 2013, [Online]. Available: https://doi.org/10.1016/j.jamda.2013.05.021. PMID: 23867520. [Accessed: Jun. 10, 2026].
  8. G. M. Tinsley, S. Nadolsky, "Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: a case series," SAGE Open Medical Case Reports, vol. 13, 2025, [Online]. Available: https://doi.org/10.1177/2050313X251388724. PMID: 41122508. [Accessed: Jun. 10, 2026].